Xarelto(Bayer/Janssen) sub group analysis of TIMI trial shows reduction in mortality for ACS patients

A major subgroup analysis from the ATLAS ACS 2-TIMI 51 study of 7,817 patients with ACS and a recent ST-segment elevation myocardial infarction (STEMI) demonstrated that oral anticoagulant Xarelto (rivaroxaban) 2.5 mg twice daily, from Bayer/Janssen, when added to standard antiplatelet therapy, provides a significant mortality benefit. The analysis showed that adding rivaroxaban to standard antiplatelet therapy significantly reduced the composite primary efficacy endpoint (cardiovascular death, myocardial infarction (MI) or stroke) compared to standard antiplatelet therapy alone. Rates of TIMI major bleeding (not related to coronary artery bypass graft (CABG) surgery) were increased with rivaroxaban. But importantly, rivaroxaban did not increase the rate of fatal bleeding. Overall, the addition of rivaroxaban 2.5 mg twice daily significantly reduced mortality, including cardiovascular death and all cause death, in comparison to standard therapy alone. These results were presented today at the ESC Congress 2012 (European Society of Cardiology), by Dr. Jessica Mega from the TIMI Study Group.C.